Jennifer S. Smith

Jennifer S. Smith

Auto-generated profile, based on publicly available information

Jennifer S. Smith

A.Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States (US)

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JSJennifer S. Smith
Jennifer S. Smith
LLLisa Lindsay
Lisa Lindsay
BHBrooke Hoots
Brooke Hoots
JKJessica Keys
Jessica Keys
SFSilvia Franceschi
Silvia Franceschi
GCGary M. Clifford
Gary M. Clifford
Data on human papillomavirus (HPV) type distribution in invasive and pre‐invasive cervical cancer is essential to predict the future impact of HPV16/18 vaccines and HPV‐based screening tests. A meta‐analyses of HPV type distribution in invasive cervical cancer (ICC) and high‐grade squamous intraepithelial lesions (HSIL) identified a total of 14,595 and 7,094 cases, respectively. In ICC, HPV16 was the most common, and HPV18 the second most common, type in all continents. Combined HPV16/18 prevalence among ICC cases was slightly higher in Europe, North America and Australia (74–77%) than in Africa, Asia and South/Central America (65–70%). The next most common HPV types were the same in each continent, namely HPV31, 33, 35, 45, 52 and 58, although their relative importance differed somewhat by region. HPV18 was significantly more prevalent in adeno/adenosquamous carcinoma than in squamous cell carcinoma, with the reverse being true for HPV16, 31, 33, 52 and 58. Among HSIL cases, HPV16/18 prevalence was 52%. However, HPV 16, 18 and 45 were significantly under‐represented, and other high‐risk HPV types significantly over‐represented in HSIL compared to ICC, suggesting differences in type‐specific risks for progression. Data on HPV‐typed ICC and HSIL cases were particularly scarce from large regions of Africa and Central Asia.

16 March 2009 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BHBrooke E. Hoots
Brooke E. Hoots
JPJoel M. Palefsky
Joel M. Palefsky
JPJeanne M. Pimenta
Jeanne M. Pimenta
JSJennifer S. Smith
Jennifer S. Smith

15 May 2008 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Jill KoshiolJill Koshiol
Jill Koshiol
LLLisa Lindsay
Lisa Lindsay
JPJeanne M. Pimenta
Jeanne M. Pimenta
CPCharles Poole
Charles Poole
DJDavid Jenkins
David Jenkins
JSJennifer S. Smith
Jennifer S. Smith
Detection of persistent cervical carcinogenic human papillomavirus (HPV) DNA is used as a marker for cervical cancer risk in clinical trials. The authors performed a systematic review and meta-analysis of the association between persistent HPV DNA and high-grade cervical intraepithelial neoplasia (CIN2-3), high-grade squamous intraepithelial lesions (HSIL), and invasive cervical cancer (together designated CIN2-3/HSIL+) to evaluate the robustness of HPV persistence for clinical use. MEDLINE and Current Contents were searched through January 30, 2006. Relative risks (RRs) were stratified by HPV comparison group. Of 2,035 abstracts, 41 studies were eligible for inclusion in the meta-analysis. Over 22,500 women were included in calculation of RRs for persistent HPV DNA detection and cervical neoplasia. RRs ranged from 1.3 (95% confidence interval: 1.1, 1.5) to 813.0 (95% confidence interval: 168.2, 3,229.2) for CIN2-3/HSIL+ versus 12 months), wider testing intervals, CIN2-3/HSIL+, and use of an HPV-negative reference group were consistently associated with higher RRs. Thus, HPV persistence was consistently and strongly associated with CIN2-3/HSIL+, despite wide variation in definitions and study methods. The magnitude of association varied by duration of persistence and testing interval. Precise definition and standardization of HPV testing, sampling procedure, and test interval are needed for reliable clinical testing. These findings validate HPV persistence as a clinical marker and endpoint.

11 December 2008 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
DBDanielle M. Backes
Danielle M. Backes
RKRobert J. Kurman
Robert J. Kurman
JPJeanne M. Pimenta
Jeanne M. Pimenta
JSJennifer S. Smith
Jennifer S. Smith

1 October 2008 in Journal of Adolescent Health
Verified
Journal Article
Closed access
JSJennifer S. Smith
Jennifer S. Smith
AMAmy Melendy
Amy Melendy
RRRashida K. Rana
Rashida K. Rana
JPJeanne M. Pimenta
Jeanne M. Pimenta

1 April 2009 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
JSJennifer S. Smith
Jennifer S. Smith
DBDanielle M. Backes
Danielle M. Backes
BHBrooke E. Hoots
Brooke E. Hoots
RKRobert J. Kurman
Robert J. Kurman
JPJeanne M. Pimenta
Jeanne M. Pimenta
Data on human papillomavirus (HPV) prevalence in vulvar and vaginal cancers are limited. These data are important to predict the potential future effect of prophylactic HPV vaccines. Our aim was to conduct a systematic review of HPV type distribution in vulvar and vaginal invasive carcinomas, vulvar intraepithelial neoplasia (VIN), and vaginal intraepithelial neoplasia. A MEDLINE search was conducted using the terms vulvar/vaginal cancer, intraepithelial neoplasia, and HPV/human papillomavirus through September 2007 with no specified start date or language restrictions. A total of 725 abstracts (564 vulvar, 161 vaginal) were reviewed, of which 67 studies (56 vulvar, 11 vaginal) met the inclusion criteria of using polymerase chain reaction (PCR) or hybrid capture assays for HPV DNA detection and having more than one case with HPV data available. This review identified 2,790 vulvar (1,379 invasive, 1,340 VIN2/3, 71 VIN1) and 315 vaginal cases (83 invasive, 166 vaginal intraepithelial neoplasia 2/3, 66 vaginal intraepithelial neoplasia 1). Most cases were from North America and Europe (87.2%), with few from Asia (5.5%) and South America (7.3%). Human papillomavirus prevalence in vulvar cancer, VIN2/3, and VIN1 was 40.1%, 80.4%, and 77.5%, respectively. HPV prevalence in vaginal cancer, vaginal intraepithelial neoplasia (VAIN)2/3, and VAIN1 was relatively higher at 65.5%, 92.6%, and 98.5%, respectively. HPV16 was the most common type in vulvar (29.3%) and vaginal (55.4%) cancers, VIN2/3 (71.2%) and VAIN2/3 (65.8%). Human papillomavirus prevalence was higher among vaginal than vulvar cases, and HPV16 accounted for most HPV-positive cases for both cancers. Although the potential effect of HPV vaccines on these gynecologic cancers may not be as high as for cervical cancer due to their more diverse causes, vaccinating young women against HPV16/18 may help to reduce the incidence of HPV-related cases.